---
title: "Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)"
description: "The objective of this study is to allow patients who have participated in the precursor study of BCI-024 in combination with BCI-049 versus placebo or BCI-"
url: "https://www.clareohealth.com/clinical-trials/NCT00731653"
---

The objective of this study is to allow patients who have participated in the precursor study of BCI-024 in combination with BCI-049 versus placebo or BCI-024 alone (Protocol #CBM-IT-01) to receive 6 weeks of open-label treatment with an increased dose of BCI-024 in combination with an increased dose of BCI-049. The safety and tolerability of this higher dose of the combination will be evaluated, as will the treatment effect in reducing symptoms of depression in patients with MDD.

## Key Facts

**ID:** NCT00731653
**Status:** COMPLETED
**Phase:** PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 81
**Sponsor:** Massachusetts General Hospital

## About This Study

This clinical trial is testing a combination of two medications, BCI-024 and BCI-049, to see how well they are tolerated and whether they help reduce symptoms of Major Depressive Disorder (MDD). It is for adults aged 18 to 65 who have previously participated in a related study.

## Detailed Description

Up to approximately 120 adult outpatients meeting the study's inclusion and exclusion criteria may be enrolled in the study.

## Conditions

- Major Depressive Disorder

## Interventions

**DRUG: Combination Product: BCI-024 + BCI-049**
BCI-024 and BCI-049 once a day at bedtime for 6 weeks

## Eligibility

Inclusion Criteria: * Subjects who are willing to provide written informed consent and who have completed participation in Protocol CBM-IT-01 are eligible for the study.

## Who Can Participate

**Minimum age:** 18

**Maximum age:** 65

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
- Synergy Research Centers, San Diego, California, United States
- Atlanta Institute of Medicine & Research, Inc., Altanta, Georgia, United States
- Capital Clinical Research Associates, Rockville, Maryland, United States
- NorthCoast Clinical Trials, Beachwood, Ohio, United States
- CRI Worldwide, Philadelphia, Pennsylvania, United States
- FutureSearch Clinical Trials, L.P., Austin, Texas, United States
- FutureSearch Trials of Dallas, L.P., Dallas, Texas, United States
- Claghorn-Lesem Research Clinic, Ltd., Houston, Texas, United States

## Contact Information

## Important Dates

**Study start:** July 1, 2008

**Completion date:** January 1, 2009

**Last updated:** December 17, 2013

## Collaborators

- BrainCells Inc.

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have previously participated in a study related to BCI-024 or BCI-049.
- You are looking for new treatment options for Major Depressive Disorder.
- You want to explore the effects of a higher dose of these medications.

### Questions to Ask

- What are the potential side effects of BCI-024 and BCI-049?
- How does this treatment compare to other options I might have?
- What should I expect during the 6 weeks of treatment?
- Will there be any monitoring or follow-up after the treatment period?
- How will we know if the treatment is working for me?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT00731653)
